Kamesh R. Sirigireddy

Kamesh R. Sirigireddy is an accomplished leader in biotechnology and vaccine development with extensive experience in the pharmaceutical and veterinary sectors. Currently serving as Director at Merck, Kamesh plays a critical role in providing strategic technical guidance for vaccine portfolio development involving Alphavirus Replicon Particle, mRNA, and plasmid DNA technologies. Prior to Merck, Kamesh held senior positions at Boehringer Ingelheim, including Senior Associate Director and Head of Ames Pets/Equine R&D, where significant contributions included leading clinical trials and establishing a successful R&D program for veterinary diagnostics. Kamesh's academic background includes a Ph.D. in Veterinary Pathobiology from Kansas State University, along with various degrees in veterinary medicine and microbiology. Recognized for innovation, Kamesh has also authored numerous publications and holds patents in vaccine development.